Evercore ISI lowered the firm’s price target on Iqvia to $265 from $270 and keeps an Outperform rating on the shares. The firm is adjusting estimates and making additions to Evercore’s “Tactical Outperform” and “Tactical Underperform” lists ahead of Q3 earnings from the Healthcare Technology and Distribution group.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IQV:
- Iqvia price target raised to $256 from $251 at Baird
- Iqvia initiated with an Outperform at RBC Capital
- Iqvia management to meet with William Blair